CLL | Tumor

Imbruvica Plus Ublituximab Safely Improves Response Rate for High-Risk Chronic Lymphocytic Leukemia

April 23rd 2021, 9:00pm


Imbruvica combined with ublituximab improved overall response rate and progression-free survival for relapsed/refractory high-risk chronic lymphocytic leukemia with minimal residual disease negativity.

Gazyva With Chemotherapy Shows Promise for Chronic Lymphocytic Leukemia

April 22nd 2021, 9:00pm


Final analysis of a phase 3 study demonstrates a tolerable toxicity profile for Gazvya in combination with chemotherapy for patients with ether first-line or relapsed/refractory chronic lymphocytic leukemia.

Your Chronic Lymphocytic Leukemia (CLL) Diagnosis

April 16th 2021, 12:00pm


Navigating life with blood cancer

Sponsored Content: CALQUENCE® (acalabrutinib) for Patients with Chronic Lymphocytic Leukemia (CLL)

March 17th 2021, 12:00pm


An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center.

Imbruvica Plus Novel Agent May Improve Progression-Free Survival in Chronic Lymphocytic Leukemia

March 3rd 2021, 7:00pm


Patients treated with Imbruvica plus TG-1101 had an overall response rate of 83% compared with 65% in those treated with Imbruvica alone.

Marialice’s Story with Chronic Lymphocytic Leukemia (CLL)

February 19th 2021, 9:30pm


Treating CLL with CALQUENCE® (acalabrutinib)

Friday Frontline: First Patient to Receive CAR-T Cell Therapy Dies, Cancer Organizations Appeal to President for COVID-19 Vaccine Priority Access, and More

February 19th 2021, 4:00pm


From the death of Bill Ludwig, the first patient to receive CAR-T cell therapy to treat his end-stage CLL, to a letter to the President urging him to grant patients with cancer and survivors priority access to the COVID-19 vaccine, here’s what’s happening in the cancer space this week.

Jim’s Story with Chronic Lymphocytic Leukemia (CLL)

February 19th 2021, 1:00pm


Treating CLL with CALQUENCE® (acalabrutinib)

Adding to the Regimen: NCCN Updates in Leukemia and Lymphoma

February 15th 2021, 4:00pm


The NCCN has updated its recommendations for chronic lymphocytic leukemia and small lymphocytic lymphoma to now include Brukinsa as a first- and second-line therapy in a subgroup of patients.

Addressing Unmet Needs in CLL

February 2nd 2021, 9:30pm